Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Non Operating Income: 2020-2025

Historic Non Operating Income for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $10.9 million.

  • Janux Therapeutics' Non Operating Income rose 40.54% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year increase of 66.73%. This contributed to the annual value of $29.9 million for FY2024, which is 103.28% up from last year.
  • As of Q3 2025, Janux Therapeutics' Non Operating Income stood at $10.9 million, which was down 2.86% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Non Operating Income registered a high of $11.4 million during Q1 2025, and its lowest value of $46,000 during Q2 2021.
  • Over the past 3 years, Janux Therapeutics' median Non Operating Income value was $7.8 million (recorded in 2024), while the average stood at $7.1 million.
  • Data for Janux Therapeutics' Non Operating Income shows a peak YoY skyrocketed of 2,874.32% (in 2022) over the last 5 years.
  • Over the past 5 years, Janux Therapeutics' Non Operating Income (Quarterly) stood at $74,000 in 2021, then spiked by 2,874.32% to $2.2 million in 2022, then soared by 98.96% to $4.4 million in 2023, then skyrocketed by 101.10% to $8.8 million in 2024, then soared by 40.54% to $10.9 million in 2025.
  • Its Non Operating Income stands at $10.9 million for Q3 2025, versus $11.3 million for Q2 2025 and $11.4 million for Q1 2025.